Luis Dabul
Psychiatry · Miami, FLNPI 1598127086
Payments from drug & device makers
Across 217 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$838
- Teva Pharmaceuticals USA, Inc.$776
- Otsuka America Pharmaceutical, Inc.$644
- AbbVie$458
- Johnson & Johnson$419
- Lundbeck LLC$287
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 44 | $838 |
| Teva Pharmaceuticals USA, Inc. | 30 | $776 |
| Otsuka America Pharmaceutical, Inc. | 27 | $644 |
| AbbVie(2 entities) | 29 | $458 |
| Johnson & Johnson | 19 | $419 |
| Lundbeck LLC | 10 | $287 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $285 |
| Almatica Pharma LLC | 9 | $215 |
| Neurocrine Biosciences, Inc. | 6 | $177 |
| Axsome Therapeutics, Inc. | 5 | $135 |
| Tris Pharma Inc | 5 | $110 |
| Indivior Inc. | 3 | $80 |
| Supernus Pharmaceuticals, Inc. | 4 | $76 |
| Braeburn Inc. | 3 | $73 |
| Ironshore Pharmaceuticals Inc. | 3 | $64 |
| Corium, LLC | 3 | $57 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Exact Sciences | 2 | $39 |
| Orexo US, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Austedo XR$119
- VRAYLAR$116
- AUSTEDO$114
How this compares
$4,808 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 24 | $69,836 |
| Abilify MaintenaAripiprazole | 27 | $64,441 |
| Abilify AsimtufiiAripiprazole | 13 | $54,220 |
| TrintellixVortioxetine Hydrobromide | 17 | $10,931 |
| Aripiprazole | 63 | $5,279 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $2,897 |
| Quetiapine Fumarate | 104 | $1,565 |
| Mirtazapine | 84 | $939 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 19 | $742 |
| Hydroxyzine Pamoate | 87 | $710 |
| Risperidone | 84 | $677 |
| Escitalopram Oxalate | 104 | $662 |
| Divalproex Sodium | 17 | $655 |
| Trazodone Hcl | 105 | $655 |
| Duloxetine Hcl | 47 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii | $644 | $118,66140 claims |
| Johnson & JohnsonInvega Sustenna | $419 | $69,83624 claims |
| Almatica Pharma LLCSertraline Hcl | $215 | $293128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.